<DOC>
	<DOCNO>NCT01442545</DOCNO>
	<brief_summary>The purpose study evaluate effect JNJ-39758979 pharmacokinetics ( body handle drug ) methotrexate participant rheumatoid arthritis .</brief_summary>
	<brief_title>A Study Investigate How JNJ-39758979 May Affect Plasma Levels Methotrexate Rheumatoid Arthritis Participants</brief_title>
	<detailed_description>This open-label ( physician participant know name assign drug ) , multi-center , non-randomized , drug-drug interaction study JNJ-39758979 participant rheumatoid arthritis ( RA ) stable oral methotrexate ( MTX ) dose ( 7.5 - 25 mg ) . The treatment phase last 17 day . Participants house clinic dosing study procedure Day -1 Day 3 Day 13 Day 17 . Participants complete treatment follow-up visit Days 22 25 . Participants discontinue study prematurely complete Day 22 25 follow-up procedure time discontinuation soon possible , thereafter . The length participation study individual participant may 9 week ( include screen ) . Participant safety monitor . Day 1 : A single oral dose participant 's weekly methotrexate dose . Days 3-15 : Weekly MTX co-administered three 100-mg , enteric-coated tablet JNJ-39758979 , administer daily .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis Functional Class IIII accord American College Rheumatology criterion least 3 month prior Screening Have treat tolerate oral methotrexate ( take mouth ) minimum 3 month prior screen , must stable onceweekly methotrexate dose ( take single dose ) 7.5 25 mg/week minimum 1 month prior Day 1 Participants may continue stable nonsteroidal antiinflammatory drug ( NSAID ) and/or corticosteroid background therapy rheumatoid arthritis ( RA ) stable therapy condition prescribe physician , provide dos therapy stable least 1 month prior screen remain unchanged entire study duration Medically stable basis physical examination , medical history , vital sign , electrocardiogram ( ECG ) perform screen Laboratory value within certain limit screen Day1 . Abnormalities consistent observe patient RA permissible . History current clinically significant medical illness specify protocol , illness investigator considers exclude participant could interfere interpretation study result Have treat monoclonal antibody RA 3 month prior enrollment serious infection within 2 week study treatment period Except methotrexate , treat approved investigational nonbiologic diseasemodifying antirheumatic drug ( DMARDs ) 4 week 5 halflives prior first dose JNJ39758979 , whichever longer . These agent include , limited Dpenicillamine , hydroxychloroquine , chloroquine , oral parenteral gold salt , sulfasalazine , leflunomide , azathioprine , cyclosporine , tacrolimus mycophenolate mofetil .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>JNJ-39758979</keyword>
	<keyword>Methotrexate</keyword>
</DOC>